{"protocolSection": {"identificationModule": {"nctId": "NCT02235298", "orgStudyIdInfo": {"id": "20140671"}, "organization": {"fullName": "University of Miami", "class": "OTHER"}, "briefTitle": "Dapagliflozin Effects on Epicardial Fat", "officialTitle": "Effects of Dapagliflozin on Epicardial Fat in Subjects With Type 2 Diabetes"}, "statusModule": {"statusVerifiedDate": "2021-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-09-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-09-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-09-04", "studyFirstSubmitQcDate": "2014-09-08", "studyFirstPostDateStruct": {"date": "2014-09-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-01-27", "resultsFirstSubmitQcDate": "2021-01-27", "resultsFirstPostDateStruct": {"date": "2021-02-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-01-27", "lastUpdatePostDateStruct": {"date": "2021-02-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Gianluca Iacobellis", "investigatorTitle": "Professor of Clinical Medicine", "investigatorAffiliation": "University of Miami"}, "leadSponsor": {"name": "University of Miami", "class": "OTHER"}, "collaborators": [{"name": "AstraZeneca", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The purpose of this research study is to learn about the effect of Dapagliflozin (Farxiga) on the fat of the heart."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"], "keywords": ["epicardial fat", "diabetes", "dapagliflozin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 100, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dapagliflozin and Metformin Group", "type": "EXPERIMENTAL", "description": "Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.", "interventionNames": ["Drug: Dapagliflozin", "Drug: Metformin"]}, {"label": "Metformin and Placebo Group", "type": "ACTIVE_COMPARATOR", "description": "Participants in this group will receive Metformin and Placebo for 6 months.", "interventionNames": ["Drug: Metformin", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Dapagliflozin", "description": "5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.", "armGroupLabels": ["Dapagliflozin and Metformin Group"], "otherNames": ["Farxiga"]}, {"type": "DRUG", "name": "Metformin", "description": "500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL", "armGroupLabels": ["Dapagliflozin and Metformin Group", "Metformin and Placebo Group"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo pill taken once daily to mimic Dapagliflozin", "armGroupLabels": ["Metformin and Placebo Group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Epicardial Fat Thickness", "description": "Epicardial fat thickness will be measured in millimeters by treating physician using echocardiography at Baseline, 12 weeks, 24 weeks", "timeFrame": "At Baseline, 12 weeks, 24 weeks"}], "secondaryOutcomes": [{"measure": "Left Ventricular Mass (LVM)", "description": "LVM will be measured in g/m\\^2 by treating physician using echocardiography at baseline, Week 12 and Week 24", "timeFrame": "At Baseline, Week 12 and Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes, as defined by ADA criteria\n* HbA1c \\< 8% measured at least 1 week prior to the study\n* BMI \u226527 kg/m2\n* Pre-treatment with Metformin as monotherapy\n* Age \\> 18 and \\< 65 years old\n* Normal and stable hemodynamic status\n\nExclusion Criteria:\n\n* Known contra-indications to Farxiga, in accordance with risks and safety information included in the latest updated Prescribing Information\n* Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria\n* Insulin dependent or treated type 2 diabetes\n* Current use of other SGLT2 inhibitors, Glucagon Like Peptide -1 (GLP- 1) analogs or Dipeptidyl Peptidase 4 (DPP4) inhibitors\n* Glomerular Filtration Rate (GFR) \\< 60 mL/min/1.73 m2\n* Signs or symptoms of hypovolemia\n* Patients with poor glycemic control (HbA1c \u2265 8%) will be excluded to maximize long-term patient retention without need\n* History of diabetes ketoacidosis\n* Patients with active bladder cancer or with a prior history of bladder cancer\n* Acute or chronic infective, including genital mycotic infections\n* Clinical signs or symptoms of New York Heart Association (NYHA) class III-IV heart failure\n* Clinical or laboratory evidences of chronic active liver diseases\n* Acute or chronic infective diseases\n* Cancer or chemotherapy\n* Current use of systemic corticosteroids or in the 3 months prior this study\n* Known or suspected allergy to Dapagliflozin, excipients, or related products\n* Pregnant, breast-feeding or the intention of becoming pregnant\n* Females of childbearing potential who are not using adequate contraceptive methods", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "64 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Gianluca Iacobellis, MD, PhD", "affiliation": "University of Miami", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Miami", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Dapagliflozin and Metformin Group", "description": "Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.\n\nDapagliflozin: 5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.\n\nMetformin: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL"}, {"id": "FG001", "title": "Metformin and Placebo Group", "description": "Participants in this group will receive Metformin and Placebo for 6 months.\n\nMetformin: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL\n\nPlacebo: Placebo pill taken once daily to mimic Dapagliflozin"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "50"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "42"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Dapagliflozin and Metformin Group", "description": "Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.\n\nDapagliflozin: 5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.\n\nMetformin: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL"}, {"id": "BG001", "title": "Metformin and Placebo Group", "description": "Participants in this group will receive Metformin and Placebo for 6 months.\n\nMetformin: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL\n\nPlacebo: Placebo pill taken once daily to mimic Dapagliflozin"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "100"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52", "spread": "9"}, {"groupId": "BG001", "value": "51", "spread": "11"}, {"groupId": "BG002", "value": "51.5", "spread": "10"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "59"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "41"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "47"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "53"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Epicardial Fat Thickness", "description": "Epicardial fat thickness will be measured in millimeters by treating physician using echocardiography at Baseline, 12 weeks, 24 weeks", "populationDescription": "Data is reported only for the participants that completed the study intervention.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm", "timeFrame": "At Baseline, 12 weeks, 24 weeks", "groups": [{"id": "OG000", "title": "Dapagliflozin and Metformin Group", "description": "Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.\n\nDapagliflozin: 5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.\n\nMetformin: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL"}, {"id": "OG001", "title": "Metformin and Placebo Group", "description": "Participants in this group will receive Metformin and Placebo for 6 months.\n\nMetformin: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL\n\nPlacebo: Placebo pill taken once daily to mimic Dapagliflozin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "42"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.6", "spread": "2.2"}, {"groupId": "OG001", "value": "8.0", "spread": "2.5"}]}]}, {"title": "12 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.2", "spread": "2.3"}, {"groupId": "OG001", "value": "7.4", "spread": "2.5"}]}]}, {"title": "24 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.7", "spread": "2.1"}, {"groupId": "OG001", "value": "7.5", "spread": "2.4"}]}]}]}, {"type": "SECONDARY", "title": "Left Ventricular Mass (LVM)", "description": "LVM will be measured in g/m\\^2 by treating physician using echocardiography at baseline, Week 12 and Week 24", "populationDescription": "Due to time and technical limitations, LVM data were not collected for all participants that completed the study intervention.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/m^2", "timeFrame": "At Baseline, Week 12 and Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin and Metformin Group", "description": "Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.\n\nDapagliflozin: 5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.\n\nMetformin: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL"}, {"id": "OG001", "title": "Metformin and Placebo Group", "description": "Participants in this group will receive Metformin and Placebo for 6 months.\n\nMetformin: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL\n\nPlacebo: Placebo pill taken once daily to mimic Dapagliflozin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "129", "spread": "13"}, {"groupId": "OG001", "value": "130", "spread": "19"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "127", "spread": "18"}, {"groupId": "OG001", "value": "128", "spread": "20"}]}]}, {"title": "Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "122", "spread": "19"}, {"groupId": "OG001", "value": "122", "spread": "20"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "24 Weeks", "eventGroups": [{"id": "EG000", "title": "Dapagliflozin and Metformin Group", "description": "Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.\n\nDapagliflozin: 5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.\n\nMetformin: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL", "deathsNumAffected": 0, "deathsNumAtRisk": 50, "seriousNumAffected": 0, "seriousNumAtRisk": 50, "otherNumAffected": 8, "otherNumAtRisk": 50}, {"id": "EG001", "title": "Metformin and Placebo Group", "description": "Participants in this group will receive Metformin and Placebo for 6 months.\n\nMetformin: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL\n\nPlacebo: Placebo pill taken once daily to mimic Dapagliflozin", "deathsNumAffected": 0, "deathsNumAtRisk": 50, "seriousNumAffected": 0, "seriousNumAtRisk": 50, "otherNumAffected": 2, "otherNumAtRisk": 50}], "otherEvents": [{"term": "Urinary Tract Infection", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "Balanitis", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 50}]}, {"term": "Abdominal Distention", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 50}]}, {"term": "Frequency of Urination", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "Dysuria", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 50}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Gianluca Iacobellis, MD", "organization": "University of Miami", "email": "giacobellis@miami.edu", "phone": "305-243-3636"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2014-09-24", "uploadDate": "2021-01-12T13:22", "filename": "Prot_SAP_000.pdf", "size": 418235}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000529054", "term": "Dapagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}